Dr. Marc Webster is a Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Canada and is a Clinical Assistant Professor in Oncology at the University of Calgary. Dr. Webster is also the Southern Alberta Breast Clinical Trials Group Leader and an Executive Member of the Southern Alberta Head and Neck Group. Dr. Webster’s research focuses on the investigational use of novel anti-angiogenic agents and optimal use of approved endocrine and chemotherapies for patients with metastatic breast cancer. Dr. Webster received his MD from the University of Ottawa and his PhD in molecular sciences from McMaster University where he focused on key signaling pathways in mammary tumorgenesis and helped define the role of HER2 and phosphoinositide 3-kinase (PI3K) pathways in breast cancer.
Clinical Advisory Board
Dr. John DiPersio is the Deputy Director of the Siteman Cancer Center, Virginia E. and Samuel J. Golman Endowed Professor of Oncology, and Chief, Division of Oncology at Washington University School of Medicine in St. Louis, MO. Dr. DiPersio’s research focuses on fundamental and translational aspects of leukemia and stem cell biology and transplantation. Dr. DiPersio is a member of the Board of Scientific Counselors of the National Cancer Institute, the 2014 recipient of the AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research, and the 2014 recipient of the American Society of Hematology Mentor Award for Clinical Investigations. He has authored or co-authored more than 275 publications and over 60 invited reviews and book chapters. Dr. DiPersio received his MD and PhD from the University of Rochester where he was the Director of the Bone Marrow Transplant Program. Dr. DiPersio was a fellow in the Division of Hematology/Oncology at University of California, Los Angeles and completed an internship and residency at the UT-Southwestern Medical Center.
Dr. Mark Pegram is the Suzy Yuan-Huey Hung Professor of Medicine at the Stanford Cancer Institute. During his career path to tenured full professor at UCLA, Dr. Pegram, in collaboration with Dr. Dennis Slamon at UCLA, and scientists at Genentech, Inc., played a significant role in the pre-clinical and early clinical development of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer. In 2012, he was recruited to the SCI from the Sylvester Comprehensive Cancer Center, where he served as the Associate Director for Clinical Research, and acting Division Chief of Hematology/Oncology for a faculty of over 70 researchers. In 2013, he assumed the role of Associate Director for Clinical Research within the SCI. He is a breast cancer physician and researcher who has chaired the DOD breast cancer research program panel and is the recipient of the NCI Director’s Service Award, the Sylvester Outstanding Cancer Research Award, the Hope Award from the HERS Breast Cancer Foundation, and is a Fellow of the Breast Cancer Research Foundation. His research focuses on new therapeutic strategies targeting HER2-positive breast cancers. Dr. Pegram was the lead author on the papers describing pre-clinical synergy between multiple chemotherapeutics and trastuzumab, and the first phase II clinical trial of trastuzumab plus chemotherapy. In addition, he was the senior author of the pivotal trial of letrozole plus lapatinib – leading to an FDA approval and co-author on the pivotal trials of trastuzumab plus chemotherapy, and T-DM1 (Kadcyla®), both published in the New England Journal of Medicine, and leading to FDA approvals. Along with Dr. George Sledge, Dr. Pegram co-directs SCI’s newest program area: the Translational Oncology Program at Stanford (TOPS).
Mike Gresser received his Ph.D in Biochemistry in 1976 from Brandeis University, and completed postdoctoral studies at the Molecular Biology Institute at UCLA on the mitochondrial and chloroplast proton translocating ATP synthases. In 1980 Mike joined the Department of Chemistry at Simon Fraser University in British Columbia, where he served as Assistant Professor, Associate Professor, and Professor of Chemistry. In 1988 Mike joined Merck & Co., Inc. as Director of Biochemistry at the Merck Frosst Center for Therapeutic Research, and was eventually promoted Executive Director of Biochemistry and Molecular Biology. In 2000 Mike joined Amgen, where he remained until 2006. While at Amgen he served as VP, Research for Inflammation and later as Head of Neuroscience Research and Inflammation Research. Subsequently, Mike also served as the Interim Chief Scientific Officer at Oxford BioTherapeutics between 2009 and 2010, CSO at the Myelin Repair Foundation, and is currently a Visiting Scholar at the Molecular Biology Institute at UCLA as well as Chief Scientific Officer at ImmunGene.